GGrantIndex
Sort

40,608 grants matching prostate cancer

GPR30 and hepatic cholesterol metabolism

$467,461
David Q Wang · Albert Einstein College Of Medicine · R01 · FY2020 · DK

Tumor Detection and Classification using QUS Technology's Structure Function

$467,423
William D. O'Brien · University Of Illinois At Urbana-Champaign · R01 · FY2022 · CA

Control of lethal prostate cancer with a bispecific av and a5b1 integrin antibody

$467,360
Paul Mathew · Tufts Medical Center · R01 · FY2022 · CA

Delineate the Role of GSTP1 in Advanced Prostate Cancer

$467,334
Tanya I Stoyanova · University Of California Los Angeles · R01 · FY2023 · CA

Cancer Nanotechnology in Imaging and Radiotherapy

$467,264
Gayle E Woloschak · Northwestern University At Chicago · R25 · FY2011 · CA

Enhancing the efficacy of androgen signaling inhibitors in prostate cancer

$467,258
Xiaoqi Liu · University Of Kentucky · R01 · FY2021 · CA

PheWAS and GWAS of Telomere Length to Understand Human Disease

$467,221
Scott Joseph Hebbring · Marshfield Clinic Research Foundation · R01 · FY2021 · GM

PROSTATE CANCER IN MEXICANS AMERICANS &AFRICAN AMERICAN

$467,204
University Of Texas Md Anderson Can Ctr · R01 · FY2001 · CA

Biology of AR+ prostate cancer metastases and the role of the microenvironment

$467,174
Kathleen Kelly · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA

Quantitative histopathology for cancer prognosis using quantitative phase imaging on stained tissues

$467,172
Mark A Anastasio · University Of Illinois At Urbana-Champaign · R01 · FY2023 · CA

NOVEL PROSTATE CANCER GENE AND MONOCLONAL ANTIBODY

$467,166
Columbia University Health Sciences · R01 · FY2002 · CA

Resolving ensemble averaged conformations by multi-temperature x-ray crystallography

$467,162
James Solomon Fraser · University Of California, San Francisco · R01 · FY2021 · GM

Structure and dynamics of clinically-relevant cytochrome P450 enzymes

$467,156
Emily E Scott · University Of Michigan At Ann Arbor · R01 · FY2019 · GM

Role of Tumor Stem Cells Recurrent Prostate Cancer

$467,053
Gary Smith · Univ Of North Carolina Chapel Hill · P01 · FY2011 · CA

Hybrid Plasma Markers that Complement CT Imaging for Early Lung Cancer Detection

$467,030
Paul D Lampe · Fred Hutchinson Cancer Research Center · U01 · FY2019 · CA

Elucidating the Molecular Role of SYNCRIP in Prostate Cancer and AR Targeted Therapy Resistance

$467,016
Ping Mu · Yale University · R37 · FY2024 · CA

Use of Geographic Variations to Estimate Effectiveness with Non-Randomized Data

$467,006
Mary Beth Landrum · Harvard Medical School · R01 · FY2012 · CA

COMBING CAR T CELLS WITH BLOCKADE OF TUMOR-INDUCED IMMUNOSUPPRESSION TO TARGET METASTATIC PROSTATE CANCER

$466,981
Beckman Research Institute Of The City Of Hope · · FY2017 · Department of the Army

PSMA Antibody-Drug Conjugate for Prostate Cancer Therapy

$466,948
Dangshe Ma · Progenics Pharmaceuticals, Inc. · R44 · FY2008 · CA

PROSTATE CANCER--FAMILY CARE FOR PATIENTS AND SPOUSES

$466,948
University Of Michigan At Ann Arbor · R01 · FY2002 · CA

OHSU Center for Specialized Data Analysis as part of the GDAN

$466,877
Paul T Spellman · Oregon Health & Science University · U24 · FY2019 · CA

Genetic Susceptibility And The Environment In Cancer Risk

$466,847
Jack A Taylor · National Institute Of Environmental Health Sciences · ZIA · FY2021 · ES

Research Infrastructure Core

$466,815
Valerie Odero-Marah · Clark Atlanta University · U54 · FY2021 · MD

IDENTIFICATION OF RECESSIVE PROSTATE CANCER RISK ALLELES IN THE MILLION VETERANS PROGRAM

$466,809
Icahn School Of Medicine At Mount Sinai · · FY2025 · Defense Health Agency

miRNA Expression Profiling

$466,613
David M Brown · Ambion Diagnostics, Inc. · R44 · FY2007 · CA